Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
M. Asunción, R.M. Calvo, J.L. San Millán, J. Sancho, S. Ávila, H. Escobar-Morreale.
A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.
J Clin Endocrinol Metab, 85 (2000), pp. 2434-2438
[2.]
I.F. Stein, M.L. Leventhal.
Amenorrhea associated with bilateral polycystic ovaries.
Am J Obstet Gynecol, 29 (1935), pp. 181-191
[3.]
A.E. Taylor.
Polycystic ovary syndrome.
Endocrinol Metab Clin North Am, 27 (1998), pp. 877-902
[4.]
D.A. Ehrmann, R.B. Barnes, R.L. Rosenfield.
Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion.
Endocr Rev, 16 (1995), pp. 322-353
[5.]
R.L. Rosenfield.
Current concepts of polycystic ovary syndrome.
Baillière's Clin Obstet Gynaecol, 11 (1997), pp. 307-333
[6.]
J.K. Zawadzki, A. Dunaif.
Diagnostic criteria for polycystic ovary syndrome: towards a rational approach.
Polycystic ovary syndrome. Current Issues in endocrinology and metabolism, pp. 4
[7.]
S. Robinson, A.D. Henderson, S.V. Gelding, D. Kiddy, R. Niththyananthan, A. Bush, et al.
Dyslipidemia is associated with insulin resistance in women with polycystic ovaries.
Clin Endocrinol, 44 (1996), pp. 277-284
[8.]
J.P. Després, B. Lamarche, P. Mauriège, B. Cantin, G. Dagenais, S. Moorjani, et al.
Hyperinsulinemia as an independent risk factor for ischemic heart disease.
N Engl J Med, 334 (1996), pp. 952-957
[9.]
E. Ferrannini, S.M. Haffner, B.D. Mitchell, M.P. Stern.
Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome.
Diabetologia, 34 (1991), pp. 416-422
[10.]
U. Goldbourt, S. Yaari, J.H. Medalie.
Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 107-113
[11.]
R.A. De Fronzo, E. Ferrannini.
Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and aterosclerotic cardiovacular disease.
Diabetes Care, 14 (1991), pp. 173-194
[12.]
R.S. Legro, A.R. Kunselman, W.C. Dodson, A. Dunaif.
Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycistic ovary syndrome: a prospective, controlled study in 254 affected women.
J Clin Endocrinol Metab, 84 (1999), pp. 165-169
[13.]
D. Cibula, R. Cífková, M. Fanta, R. Poledne, J. Zivny, J. Skibová.
Increased risk of noninsulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovari syndrome.
Hum Reprod, 15 (2000), pp. 785-789
[14.]
K.J. Mather, F. Kwan, B. Corenblum.
Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity.
Fertil Steril, 73 (2000), pp. 150-156
[15.]
K.H. Polderman, L.J.G. Gooren, H. Asscheman, A. Bakker, R. Heine.
Induction of insulin resistance by androgens and estrogens.
J Clin Endocrinol Metab, 79 (1994), pp. 265-271
[16.]
M.P. Diamond, D. Grainger, M.C. Diamond, R.S. Sherwin, R.A. Defronzo.
Effects of methyltestosterone on insulin secretion and sensitivity in women.
J Clin Endocrinol Metab, 83 (1998), pp. 4420-4425
[17.]
S. Nader, M.G. Riad-Gabriel, M.F. Saad.
The effect of a desogestrel containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.
J Clin Endocrinol Metab, 82 (1997), pp. 3074-3077
[18.]
L.C. Morin-Papunen, I. Vauhkonen, R.M. Koivunen, A. Ruokonen, H.K. Martikainen, J.S. Tapanainen.
Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
J Clin Endocrinol Metab, 85 (2000), pp. 3161-3168
[19.]
P.O. Dale, T. Tanbo, O. Djoseland, J. Jervell, T. Abyholm.
Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist.
Acta Endocrinol, 126 (1992), pp. 132-136
[20.]
V. De Leo, D. Lanzetta, D. D'Antona, A. La Marca, G. Morgante.
Hormonal effects of flutamide in young women with polycystic ovary syndrome.
J Clin Endocrinol Metab, 83 (1998), pp. 99-102
[21.]
E. Diamanti-Kandarakis, A. Mitrakou, S. Raptis, G. Tolis, A.J. Duleba.
The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.
J Clin Endocrinol Metab, 83 (1998), pp. 2699-2705
[22.]
L. Ibanez, N. Potau, M.V. Marcos, F. De Zegher.
Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in non-obese, adolescent girls: effect of flutamide.
J Clin Endocrinol Metab, 85 (2000), pp. 3251-3255
[23.]
E. Diamanti-Kandarakis, A. Mitrakou, M.M. Hennes, D. Platanissiotis, N. Kaklas, J. Spina, et al.
Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
Metabolism, 44 (1995), pp. 525-531
[24.]
S. Venturoli, O. Marescalchi, F.M. Colombo, S. Macrelli, B. Ravaioli, A. Bagnoli, et al.
A prospective randomized trial comparing low dose flutamide, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism.
J Clin Endocrinol Metab, 84 (1999), pp. 1304-1310
[25.]
J.E. Nestler.
Role of hyperinsulinemia in the pathogenesis of the polycistic ovary syndrome, and its clinical implications.
Semin Reprod Endocrinol, 15 (1997), pp. 111-122
[26.]
A. Dunaif.
Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.
Endocr Rev, 18 (1997), pp. 774-800
[27.]
R.L. Barbieri, A. Makris, R.W. Randall, G. Daniels, R.W. Kristner, K.J. Ryan.
Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism.
J Clin Endocrinol Metab, 62 (1986), pp. 904-910
[28.]
S.B. Kristiansen, A. Endoh, P.R. Casson, P.R. Buster, J.E. Buster, P.J. Hornsby.
Induction of steroidogenic enzyme genes by insulin and IGF-I in cultured adult human adrenocortical cells.
Steroids, 62 (1997), pp. 258-265
[29.]
J.E. Nestler, D.J. Jakubowicz.
Evidence that hyperinsulinemia induces dysregulation of P450c17 activity and increases serum free testosterone in the polycystic ovary syndrome.
N Engl J Med, 335 (1996), pp. 617-623
[30.]
P. Moghetti, R. Castello, C. Negri, F. Tosi, G.G. Spiazzi, E. Brun, et al.
Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20 lyase activity.
J Clin Endocrinol Metab, 81 (1996), pp. 881-886
[31.]
A.M. Suikkary, V.A. Koivisto, E.M. Rutanen, H. Yki-Jarvinen, S.L. Karonen, M. Seppala.
Insulin regulates the serum levels of low molecular weight insuline-like growth factor-binding protein.
J Clin Endocrinol Metab, 66 (1988), pp. 266-272
[32.]
S.R. Plymate, R.C. Hoop, R.E. Jones, L.A. Matej.
Regulation of sex hormone-bonding globulin production by growth factors.
Metabolism, 39 (1990), pp. 967-970
[33.]
E.M. Velazquez, S. Mendoza, T. Hamer, F. Sosa, C.J. Glueck.
Metformin therapy in polycystic ovary syndrome reduced hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Metabolism, 43 (1994), pp. 647-654
[34.]
J.E. Nestler, D.J. Jakubowicz.
Decreases in ovarian cytochrome P450c17α activity and serum testosterone after reduction in insulin secretion in polycystic ovary syndrome.
N Engl J Med, 335 (1996), pp. 617-623
[35.]
J.E. Nestler, D.J. Jakubowicz.
Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens.
J Clin Endocrinol Metab, 82 (1997), pp. 4075-4079
[36.]
P. Moghetti, R. Castello, C. Negri, F. Tosi, F. Perrone, M. Caputo, et al.
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, longterm clinical evaluation.
J Clin Endocrinol Metab, 85 (2000), pp. 139-146
[37.]
A. La Marca, G. Morgante, T. Paglia, L. Ciotta, A. Cianci, V. De Leo.
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome.
Fertil Steril, 72 (1999), pp. 985-989
[38.]
J.E. Nestler, D.J. Jakuobwicz, W.S. Evans, R. Pasquali.
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
N Engl J Med, 338 (1998), pp. 1876-1880
[39.]
V. De Leo, A. La Marca, A. Ditto, G. Morgante, A. Cianci.
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.
Fertil Steril, 72 (1999), pp. 282-285
[40.]
A. Dunaif, D. Scott, D. Finegood, B. Quintana, R. Whitcomb.
The insulinsensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
J Clin Endocrinol Metab, 81 (1996), pp. 3299-3306
[41.]
I. Hasegawa, H. Murakawa, M. Suzuki, Y. Yamamoto, T. Kurabayashi, K. Tanaka.
Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.
Fertil Steril, 71 (1999), pp. 323-327
[42.]
E.M. Velazquez, S.G. Mendoza, P. Wanf, C.J. Glueck.
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
Metabolism, 46 (1997), pp. 454-457
[43.]
D.A. Ehrmann, D.J. Schneider, B.E. Sobel, M.K. Cavaghan, J. Imperial, R.L. Rosenfield, et al.
Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
J Clin Endocrinol Metab, 82 (1997), pp. 2108-2116
[44.]
H.P. Kohler, P.J. Grant.
Plasminogen-activator inhibitor type 1 and coronary artery disease.
N Engl J Med, 342 (2000), pp. 1792-1801
[45.]
C.J. Bailey, M.R.C. Path, R.C. Turner.
Drug therapy. Metformin.
N Engl J Med, 334 (1996), pp. 574-579
[46.]
B.J. Stith, K. Woronoff, N. Wiernsperger.
Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin.
Biochem Pharmacol, 55 (1998), pp. 533-536
[47.]
A. Bhargava, Z. Iqbal, S. Kathula, J. Premanadan.
Metformin associated lactic acidosis (MALA) in a patient with normal renal function [resumen]. Proceedings of the 82nd Annual Meeting of the Endocrine Society.
Toronto, Canada,, 443 (2000),
[48.]
L. Ibanez, J. DiMartino-Nardi, N. Potau, P. Saenger.
Premature adrenarche .normal variant of foreunner of adult disease?.
Endocr Rev, 21 (2000), pp. 671-696
[49.]
L. Ibanez, C. Valls, N. Potau, M.V. Marcos, F. De Zegher.
Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche.
J Clin Endocrinol Metab, 85 (2000), pp. 3526-3530
[50.]
L. Ibanez, N. Potau, R. Virdis, M. Zampolli, C. Terzi, M. Gussinye, et al.
Postpubertal outcome in girls diagnose of premature pubarche during childhood: increased frequency of functional ovarian hyperandrogenism.
J Clin Endocrinol Metab, 76 (1993), pp. 1599-1603
[51.]
L. Ibanez, N. Potau, M. Zampolli, M.E. Street, A. Carrascosa.
Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: evidence from gonadotropinreleasing hormone agonist testing.
Fertil Steril, 67 (1997), pp. 849-855
[52.]
L. Ibanez, F. De Zegher, N. Potau.
Anovulation after precocious pubarche: early markers and time course in adolescence.
J Clin Endocrinol Metab, 84 (1999), pp. 2691-2695
[53.]
L. Ibanez, N. Potau, M. Zampolli, S. Rique, P. Saenger, A. Carrascosa.
Hyperinsulinemia and decrease insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche.
J Clin Endocrinol Metab, 82 (1997), pp. 2283-2288
[54.]
L. Ibanez, N. Potau, P. Chacon, C. Pascual, A. Carrascosa.
Hyperinsulinemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche.
Diabetologia, 41 (1998), pp. 1057-1063
[55.]
L. Ibanez, N. Potau, I. Francois, F. De Zegher.
Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth.
J Clin Endocrinol Metab, 83 (1998), pp. 3558-3662
[56.]
Ibáñez L, Valls C, Potau N, Marcos MV, De Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. J Clin Endocrinol Metab. En prensa
[57.]
S.E. Oberfield.
Editorial: metabolic lessons from the study of young adolescents with polycystic ovary syndrome. Is insulin, indeed, the culprit?.
J Clin Endocrinol Metab, 85 (2000), pp. 3520-3525
Copyright © 2001. Sociedad Española de Endocrinología y Nutrición